SecBot

SecBot
Nasdaq· Pharmaceutical Preparations· Inc. P7· CIK 0001830487

PHVS

Pharvaris N.V.
$31.30 ▲ +0.92%
Prev close $31.01
Market cap$2.2B
ConsensusStrong Buy
12-mo target$57.35 (+83.3%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (10 insiders)High Impact Filing (8/10) Biotech & Drug Discovery
Snapshot
The big-picture read on PHVS right now — valuation, ownership and activity at a glance.
Market Cap
$2.2B
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (90%)
Insider Activity
$0.00 buy / $23.7M sell
Insider Net $
-$23.7M
SEC Reports
20
Press Releases
9
Price chart 30d -11.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 23, 2026 Insider
Monges Viviane acquired via exercise 11,969 shares
Director @ $8.05 ($96.4K)
Sep 23, 2026 Insider
Monges Viviane sold 11,969 shares
Director @ $33.05 ($395.5K)
Sep 22, 2026 Insider
Lu Peng acquired via exercise 45,308 shares
President @ $2.59 ($117.3K)
Sep 15, 2026 SEC
Four Pharvaris insiders, including the CEO and President, sold a total of $2.15M in open-market shares over a 7-day wind
CLUSTER — Impact 5/10
Sep 15, 2026 short_volume
Short Volume: PHVS — 69.7% short (0.6M / 0.8M)
Short: 553,770 | Exempt: 719 | TRF Vol: 794,336 | Short Ratio: 69.7% | Off-exchange volume (dark poo
Sep 14, 2026 SEC
Director Berndt Modig filed a Form 144 to sell 2,291 common shares (approx. $87K) on September 14, 2026. The shares were
144 — Impact 2/10
Sep 14, 2026 SEC
Pharvaris N.V. (PHVS) — insider cluster of 3 sells totaling $2.06M over the last 7 days, led by Chief Early Development
CLUSTER — Impact 3/10
Aug 6, 2026 Press
Pharvaris announced publication of the first in-depth qualitative study in AAE-C1INH in Frontiers in Immunology, validat
Impact 4/10
Analyst ratings buy % +1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Strong Buy 90% rate it Buy or better · 21 analysts
Strong Buy 9 43% Buy 10 48% Hold 2 10% Sell 0 0% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Sep 10, 2026GuggenheimMAINTAINBuy 52%
Sep 9, 2026Morgan StanleyMAINTAINOverweight 55%
Sep 9, 2026Leerink PartnersMAINTAINOutperform 49%
Sep 9, 2026Wells FargoMAINTAINOverweight 54%
Sep 9, 2026RBC CapitalMAINTAINOutperform 55%
Sep 9, 2026CitizensMAINTAINMarket Outperform 38%
Sep 9, 2026WedbushMAINTAINOutperform 57%
Sep 8, 2026HC Wainwright & Co.REITERATEBuy 43%
Sep 8, 2026WedbushREITERATEOutperform 57%
Aug 13, 2026RBC CapitalMAINTAINOutperform 55%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 202691020090%
Aug 1, 202691020090%
Jul 1, 20269920090%
Jun 1, 20269920090%
May 1, 20269920090%
Apr 1, 20268830084%
Mar 1, 20268820089%
Feb 1, 20268820089%
Price targets
Where 14 covering analysts think PHVS trades over the next 12 months.
$57.35 +83.3% upside Strong Buy
Current$31.30 Low$41.23 Median$60.02 High$76.47 14 analysts
$41.23$76.47
Analyst rating Strong Buy· 1.4/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 2 bullish, 2 bearish, 0 mixed, 16 neutral · avg impact 3.9/10.Plus 9 press releases.
BEARISHCLUSTER5/10
Four Pharvaris insiders, including the CEO and President, sold a total of $2.15M in open-market shar
Sep 15, 2026
NEUTRAL1442/10
Director Berndt Modig filed a Form 144 to sell 2,291 common shares (approx. $87K) on September 14, 2
Sep 14, 2026
NEUTRALCLUSTER3/10
Pharvaris N.V. (PHVS) — insider cluster of 3 sells totaling $2.06M over the last 7 days, led by Chie
Sep 14, 2026
NEUTRALCLUSTER3/10
Two Pharvaris insiders, including President Lu Peng, sold a combined $911K in open-market sales this
Sep 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 15, 2026
short_volume
Short Volume: PHVS — 69.7% short (0.6M / 0.8M)
Short: 553,770 | Exempt: 719 | TRF Vol: 794,336 | Short Ratio: 69.7% | Off-exchange volume (dark pool + OTC)
Sep 8, 2026
Clinical Trial
Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II
Phase Phase 2 — TERMINATED
Sep 8, 2026
fda
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
ZUG, Switzerland, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykini
Aug 31, 2026
short_interest_report
Short Interest: PHVS up 22% to 2.2M shares
Settlement 2026-08-31 | Days to cover: 3.38 | ≈3.10% of shares outstanding (est.)
Aug 19, 2026
earnings_calendar
PHVS Q2 2026 Earnings After Market Close — 2026-08-19
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$-0.72$-0.80–$-0.65-19.5%+0.6%3↑ 8↓$0.0B11
Next Q$-0.77$-0.90–$-0.66-8.2%+0.7%3↑ 7↓$0.0B11
Current FY$-2.77$-3.01–$-2.396.9%-0.1%2↑ 9↓$0.0B13
Next FY$-2.71$-3.45–$-2.112.0%-1.2%3↑ 8↓$0.0B12
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$-0.717—
7d ago$-0.716-0.000
30d ago$-0.721+0.004
60d ago$-0.670-0.046
90d ago$-0.668-0.049
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 50 transactions. Net -$23.7M — $0.00 bought, $23.7M sold.
DateInsiderTitleTypeSharesPriceValue
Sep 23, 2026Monges VivianeDirectorEXERCISE11,969$8.05$96.4K
Sep 23, 2026Monges VivianeDirectorSELL11,969$33.05$395.5K
Sep 22, 2026Lu PengPresidentEXERCISE45,308$2.59$117.3K
Sep 22, 2026Schikan Johannes Gerardus Christiaan PetrusDirectorEXERCISE800$20.00$16.0K
Sep 22, 2026Schikan Johannes Gerardus Christiaan PetrusDirectorSELL800$36.19$29.0K
Sep 21, 2026Nassif David W.CFO / CLOSELL6,000$36.47$218.8K
Sep 21, 2026Nassif David W.CFO / CLOGIFT500——
Sep 17, 2026Modig BerndtChief Executive OfficerEXERCISE300,000$35.00$10.5M
Sep 17, 2026Glassman RobertDirectorEXERCISE14,493$18.14$262.9K
Sep 17, 2026Glassman RobertDirectorSELL14,493$38.56$558.8K
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PHVS.
Shares short
1,784,789
Settlement Sep 15, 2026
Change vs prior
-17.4%
Semi-monthly cycle
Days to cover
1.2
At avg daily volume
Of shares outstanding
≈2.6%
Estimate — not % of float
All PHVS filing & press-release reports (37)